Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis(*)

Ítems similars

• Eritoran tetrasodium (E5564) Treatment for Sepsis: Review of Preclinical and Clinical Studies
  per: Barochia, Amisha, et al.
  Publicat: (2011)
• The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death
  per: Qiu, Ping, et al.
  Publicat: (2011)
• The Surviving Sepsis Campaign's Revised Sepsis Bundles
  per: Barochia, Amisha V., et al.
  Publicat: (2013)
• Inhibition of Corneal Inflammation by the TLR4 Antagonist Eritoran Tetrasodium (E5564)
  per: Sun, Yan, et al.
  Publicat: (2008)
• Influence of severity of illness on the effects of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis
  per: Opal, SM, et al.
  Publicat: (2009)